Treatment News : Generic HIV Meds Could Save U.S. $1B a Year, But Risk Lowering Adherence

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » January 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

January 16, 2013

Generic HIV Meds Could Save U.S. $1B a Year, But Risk Lowering Adherence

As first-line HIV medications begin to lose their patents, the U.S. health care system stands to save $1 billion a year, but a switch to generics may also raise the likelihood of treatment failure, MedPage Today reports. A study conducted by Massachusetts General Hospital and Weill Cornell Medical College and published in the January 15 Annals of Internal Medicine examines both the financial and health impacts of the release of generic antiretrovirals (ARVs).

Currently, the recommended therapy for treatment-naive people with HIV is the single-pill, once-a-day triple combination therapy Atripla, which is comprised of three brand-name ARVs: Viread (tenofovir), Emtriva (emtricitabine) and Sustiva (efavirenz). In January 2012, a generic form of the ARV lamivudine, which operates similarly to emtricitabine, was released. A generic of efavirenz is expected to hit the market soon.

The study indicates that adding the two generics to Viread to assemble a combination therapy comparable to Atripla would yield a lifetime savings of $42,500 for every eligible patient. Government sources, which pay for the lion’s share of HIV care in the United States, would benefit the most. However, because of the increased pill burden—there is no imminent promise of a once-a-day generic combo pill—people with HIV would likely be less adherent to the drug cocktail and run a greater risk of developing drug resistance. Furthermore, lab studies have suggested that lamivudine may be somewhat less effective than emtricitabine, as well as more likely to lead to the development of drug resistance.

To read the MedPage Today article, click here.

To read the Mass General Hospital and Weill Cornell Medical College release, click here.

To read the abstract of the study, click here.

Editor's Note: This article has been updated.

Search: HIV, antiretrovirals, ARV, medications, patent, savings, generic, MedPage Today, Massachusetts General Hospital, Weill Cornell Medical College, Atripla, Viread, tenofovir, Emtriva, emtricitabine, Sustiva, efavirenz, lamivudine


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (5 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.